glp 1 action mechanism Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP1-GIP receptor co-agonists: a promising

Obes Rev 22:e13200 Morais JBS, Dias TMDS, Cardoso BEP, de Paiva SM, Sousa TGV, Arajo DSC, Marreiro DDN (2022) Adipose tissue dysfunction: impact on metabolic changes

This was interesting because at that time it was assumed that the best way to treat patients with metabolic disorders was not to stimulate more glucagon because it raises blood sugar, but instead to block it

Combining lower-dose folinic acid (200-800 mcg) with root cause treatment often outperforms other treatmentswith fewer side effects

Its administered as a subcutaneous injection and has been clinically tested for safety and efficacy

investigational for this use, not approved